Patenting Considerations for Artificial Intelligence in Biotech and Synthetic Biology: Part 1

Terri Shieh-Newton, PhD and Marguerite McConihe of Mintz, Levin writing in the National Law Review start a series on patenting artificial intelligence methods in the field of biotechnology and synthetic biology.

Artificial Intelligence (AI) inventions have aided development in nearly every industry, but perhaps none more so than synthetic biology. For synthetic biology researchers, AI has developed into a vital tool to create cutting edge applications. Growth is expected to accelerate with the AI healthcare market set to reach $6.6 billion by 2021, a 40 percent growth from its current size. Biotech and synthetic biology companies that use AI and investors in these companies should be aware of various legal aspects related to patenting.  This blog is part 1 of a multi-part series that explores various patenting considerations for AI in biotech and synthetic biology.

Read the rest at the link below.